Allogeneic Cell Therapy Market

Market Overview

The allogeneic cell therapy market is witnessing rapid growth, driven by its disruptive concept in biology. Traditionally, foreign tissue would trigger an immune reaction, necessitating aggressive immunosuppression in transplantation procedures. However, advancements in cell-based therapy, particularly with mesenchymal stem cells (MSCs), have revealed their ability to evade or suppress the immune system effectively. This breakthrough allows for the utilization of allografts without concomitant immunosuppression, revolutionizing the field.
Allogeneic stem cell transplants, transferring healthy blood-forming stem cells from a donor to a recipient, are crucial in treating blood cancers and immune system disorders. Unlike xenogeneic therapies, which use cells from different species, allogeneic cell therapies source cells from donors of the same species. These therapies involve expanding and potentially modifying cells from healthy donors to treat multiple patients. Stringent human donor screening and Good Manufacturing Practice (GMP) biosafety testing ensure the safety and efficacy of allogeneic cell therapies, driving market success.

Key Insights:

North America dominates the global market, with Asia-Pacific expected to grow fastest.
Stem cell therapy holds the largest revenue share, with non-stem cell therapy poised for rapid growth.
Hematological disorders lead in market share, while dermatological disorders are anticipated to grow rapidly.

Recent Developments:
•    In March 2024, Getinge and CellRev unveiled a platform to revolutionize allogeneic cell therapy manufacturing.
•    In October 2022, Allogene Therapeutics launched CAR T Together, expediting clinical trials for "off-the-shelf" allogeneic cell therapy products.

Regional Stance:
North America leads in revenue generation, supported by robust infrastructure and organizations like the American Society of Gene & Cell Therapy (ASGCT) and Americans for Medical Progress (AMP). Asia-Pacific's rapid growth reflects its burgeoning healthcare sector and conducive environment for innovation.

Market Dynamics:

Driver:
Increased demand for healthy allogeneic donors and advancements in regenerative medicine are key drivers. Partnerships with experienced entities ensure a sustainable donor supply, essential for market growth. Advancements in nanotechnology, bioengineering, and stem cell therapy amplify demand for regenerative medicine products.

Restraints:
The risk of graft-versus-host disease (GVHD) associated with allogeneic cell therapies poses a significant restraint. Mitigating GVHD risk while maintaining treatment efficacy is challenging, hindering market expansion.

Opportunities:
Advancements in allogeneic cell cancer immunotherapy present significant growth opportunities. Innovations in T-iPSC technology and the iC9 system offer promising avenues for cancer treatment, driving market expansion.

Market Segmentation:

•    By Therapy Type:
Stem Cell Therapies
Non-stem Cell Therapies

•    By Therapeutic Area:
Hematological Disorders
Dermatological Disorders
Others

•    By Geography:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
 

Recent Developments:
•    In January 2024, MaxCyte and Wugen entered into a strategic platform license agreement to expedite clinical and commercial manufacturing of allogeneic cell therapies.
•    In June 2022, Immatics and Bristol Myers Squibb expanded their strategic alliance to develop gamma delta allogeneic cell therapy programs.

Key Players:
•    SSM Cardinal Glennon Children's Medical Center
•    Cleveland Cord Blood Center
•    Duke University School of Medicine
•    New York Blood Center
•    Clinimmune Labs, University of Colorado Cord Blood Bank
•    MD Anderson Cord Blood Bank
•    LifeSouth Community Blood Centers, Inc.
•    Bloodworks Northwest
•    JCR Pharmaceuticals Co., Ltd.
•    Sumitomo Pharma Co., Ltd.
•    Atara Biotherapeutics
•    Mallinckrodt Pharmaceuticals
•    Tego Science Inc
•    Takeda Pharmaceutical Company Limited
•    STEMPEUTICS RESEARCH PVT LTD
•    Biosolution Co., Ltd.
•    MEDIPOST Co., Ltd.